ClinicalTrials.gg
SuspendedNCT04042116Updated Dec 20, 2022

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

A Phase 1/2 interventional study of Lucitanib and Lucitanib in Advanced Solid Tumor and Gynecologic Cancer, sponsored by Clovis Oncology, Inc.. Suspended at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Clovis Oncology, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was suspended
Company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
227
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.

Planned enrollment
7th of 33
227 · median 40
Started
2019
with 3 others
Phase 1/2
3 of 37
1 open now
Registered
23rd of 37
by date
Lead sponsor
1 of 37
Clovis Oncology, Inc.

Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is the 7th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 1/2, and was the 23rd registered.

Genital Neoplasms, Female

81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.

Browse Genital Neoplasms, Female studies →

Open to participants now

6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Genital Neoplasms, Female with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)

03

Conditions studied

  • Advanced Solid Tumor
  • Gynecologic Cancer

Keywords

  • lucitanib
  • nivolumab
  • antineoplastic agents immunological
  • antineoplastic agents
  • tyrosine kinase inhibitors
  • gynecologic neoplasms
  • checkpoint inhibitor
  • ovarian cancer
  • fallopian tube cancer
  • primary peritoneal cancer
  • endometrial cancer
  • clear cell cancer
  • cervical cancer
  • PD-1 inhibitor
  • Immuno-oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • ≥ 18 years of age
  • Adequate organ function
  • ≥ 3 months
  • Women of must have a negative serum pregnancy test
  • Advanced/ solid tumor (Phase 1b)
  • Availability of tumor tissue at screening
  • performance status of 0 to 1
  • ( v1.1) (Phase 2)
  • Advanced, recurrent, or metastatic gynecological solid tumor (Phase 2)
  • Willing and able to fast, and to eat a high-fat breakfast (Food Effect)

General Exclusion Criteria:

  • Prior treatment with lucitanib
  • Active second
  • Active central nervous system
  • Pre-existing duodenal stent or any gastrointestinal disorder
  • Known history of or AIDs; positive result of or C viruses
  • Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis
  • Active, known or suspected disease (eg, autoimmune hepatitis)
  • Condition requiring systemic treatment with or other immune suppressive medications
  • Unstable or uncontrolled hypertension (BP ≥ 140/90 mmHg)
  • Prior treatment with a VEGFR-tyrosine kinase inhibitor (Phase 2)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
227 participants (estimated)

Study arms

  • Experimental
    Phase 1b: Dose Escalation

    - Up to 50 patients with advanced solid tumor

    Drug: Lucitanib · Drug: Nivolumab

  • Experimental
    Phase 1b: Food Effect Cohort

    - Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled

    Drug: Lucitanib · Drug: Nivolumab

  • Experimental
    Phase 2: Expansion Cohort - Endometrial Cancer

    * Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen * Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll

    Drug: Lucitanib · Drug: Nivolumab

  • Experimental
    Phase 2: Expansion Cohort - Ovarian Cancer

    * Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma * At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy * Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll

    Drug: Lucitanib · Drug: Nivolumab

  • Experimental
    Phase 2: Expansion Cohort - Clear Cell Cancer

    * Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin * At least 1 prior platinum- and taxane-based chemotherapy regimen

    Drug: Lucitanib · Drug: Nivolumab

  • Experimental
    Phase 2: Expansion Cohort - Cervical Cancer

    * Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology * At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease

    Drug: Lucitanib · Drug: Nivolumab

Interventions

  • Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.

    Also known as: CO-3810

  • Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.

    Also known as: CO-3810

  • Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg. Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.

    Also known as: CO-3810

  • IV nivolumab 480 mg will be administered once every 4 weeks.

    Also known as: Opdivo, BMS-936558

06

What researchers measure

Primary outcomes

  1. Determine the recommended Phase 2 dose of the combination of lucitanib and nivolumab (Phase 1b)

    Incidence of adverse events and clinical lab abnormalities defined as dose-limiting toxicities and maximum tolerated dose.

    Time frame: First dose of study drug through at least 100 days after end of treatment (up to approximately 2 years)

  2. Best Overall Response Rate (Phase 2)

    Confirmed best overall response (PR or CR) based on investigator assessment of objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: From first dose of study drug until disease progression (up to approximately 2 years)

Secondary outcomes

  1. Acute and long-term safety and tolerability of the combination (Phase 2)

    Incidence of AEs, clinical lab abnormalities, and dose modifications.

    Time frame: From first dose of study drug until disease progression (up to approximately 2 years)

  2. Further evaluation of preliminary efficacy of combination (Phase 2)

    Duration of response, progression-free survival, and disease control per RECIST v1.1, overall survival.

    Time frame: From first dose of study drug until at least 100 days after end of treatment (up to approximately 2 years)

  3. Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]

    Area under the curve \[AUCss\]

    Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)

  4. Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]

    Maximum plasma concentration \[Cmax,ss\]

    Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)

  5. Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]

    Total clearance of drug after oral administration \[CLss/F\]

    Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)

  6. Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect, Phase 2]

    Minimum plasma concentration \[Cmin,ss\]

    Time frame: From Cycle 2 to Cycle 5 (each cycle is 28 days)

  7. Lucitanib PK Profile at single dose [Food Effect Cohort]

    Area under the curve \[AUC\]

    Time frame: From first dose of study drug to Day -1

  8. Lucitanib PK Profile at single dose [Food Effect Cohort]

    Maximum plasma concentration \[Cmax\]

    Time frame: From first dose of study drug to Day -1

  9. Lucitanib PK Profile at single dose [Food Effect Cohort]

    Time to maximum plasma concentration \[Tmax\]

    Time frame: From first dose of study drug to Day -1

  10. The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]

    Area under the curve \[AUC\]

    Time frame: From first dose of study drug to Day -1

  11. The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]

    Maximum plasma concentration \[Cmax\]

    Time frame: From first dose of study drug to Day -1

  12. The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]

    Time to maximum plasma concentration \[Tmax\]

    Time frame: From first dose of study drug to Day -1

07

Study locations

27 sites
  • UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • UC San Diego Moores Cancer Center
    San Diego, California 92093, United States
  • Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • NYU Langone Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University School of Medicine
    Durham, North Carolina 27710, United States
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Swedish Cancer Institute
    Seattle, Washington 98107, United States
  • Medical University of Innsbruck
    Innsbruck, 6020, Austria
  • Saint Luc Univerisity Hospital
    Brussels, 1200, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • University Hospitals Leuven, Campus Gasthuisberg
    Leuven, 3000, Belgium
  • University Hospital Carl Gustav Carus
    Dresden, 01307, Germany
  • Kliniken Essen-Mitte
    Essen, 45136, Germany
  • University Hospital Mannhein
    Mannheim, 68167, Germany
  • Polyclinic S. Orsola-Malpighi
    Bologna, 40138, Italy
  • National Cancer Institute -IRCCS "Fondazione G. Pascale
    Naples, 80131, Italy
  • Foundation IRCCS Hospital Agostino Gemelli
    Rome, 00168, Italy
  • University Hospital Reina Sofia
    Cordoba, Andalusia 14004, Spain
  • University Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Navarra University Clinic
    Madrid, 28027, Spain
  • La Paz University Hospital
    Madrid, 28046, Spain
08

References and documents

Individual participant data

Plan to share: Yes — De-identified datasets for study results will be made available to qualified researchers in compliance with applicable privacy laws and data protection regulations. Data will be provided by Clovis Oncology.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be made available to qualified researchers after the primary, secondary, and/or exploratory outcomes of the study are reported or published and for 1 year thereafter.

Access criteria: Requests for de-identified datasets will be made available to qualified researchers following submission of a methodologically sound proposal to medinfo@clovisoncology.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Jul 2023, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2019
First posted
Aug 1, 2019
StartActual
Jul 29, 2019
Primary completionEst.
Jul 2023
CompletionEst.
Jan 2024
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04042116
Lead sponsor
Clovis Oncology, Inc.
Collaborators
Bristol-Myers Squibb, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Jul 29, 2019
Primary completion
Jul 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Dec 20, 2022

Study contacts

Erika Hamilton, MD
principal investigator · Tennessee Oncology
Nicole Concin, MD
principal investigator · KEM Kliniken Essen Mitte Evang. Huyssens-Stiftung

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E-3810

Start the discussion